Chini, Claudia C. S.
Peclat, Thais R. http://orcid.org/0000-0002-8907-5548
Warner, Gina M.
Kashyap, Sonu
Espindola-Netto, Jair Machado http://orcid.org/0000-0003-0387-5059
de Oliveira, Guilherme C.
Gomez, Lilian S. http://orcid.org/0000-0002-5309-7438
Hogan, Kelly A.
Tarragó, Mariana G.
Puranik, Amrutesh S. http://orcid.org/0000-0001-7249-5602
Agorrody, Guillermo http://orcid.org/0000-0002-9241-6681
Thompson, Katie L.
Dang, Kevin
Clarke, Starlynn
Childs, Bennett G. http://orcid.org/0000-0001-6078-0588
Kanamori, Karina S.
Witte, Micaela A.
Vidal, Paola
Kirkland, Anna L.
De Cecco, Marco
Chellappa, Karthikeyani
McReynolds, Melanie R. http://orcid.org/0000-0001-5427-2739
Jankowski, Connor http://orcid.org/0000-0003-1247-4548
Tchkonia, Tamara http://orcid.org/0000-0003-4623-7145
Kirkland, James L. http://orcid.org/0000-0003-1676-4905
Sedivy, John M.
van Deursen, Jan M.
Baker, Darren J.
van Schooten, Wim
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Baur, Joseph A. http://orcid.org/0000-0001-8262-6549
Chini, Eduardo N. http://orcid.org/0000-0003-1555-4834
Article History
Received: 1 February 2019
Accepted: 10 September 2020
First Online: 16 November 2020
Competing interests
: E.N.C. holds a patent on the use of CD38 inhibitors for metabolic diseases that is licensed by Elysium health. E.N.C. is a consultant for TeneoBio, Calico, Mitobridge and Cytokinetics. E.N.C. is on the advisory board of Eolo Pharma. W.v.S. is the Chief Scientific Officer of Teneobio, a company interested in the development of therapeutic antibodies. W.v.S., K.D., E.N.C. and S.C. own stocks in Teneobio. J.L.K., T.T., J.M.v.D. and D.J.B. have a financial interest related to this research: patents on transgenic animals capable of being induced to delete senescent cells are held by the Mayo Clinic. J.L.K., T.T., D.J.B. and J.M.v.D. are co-inventors on patent applications licensed to or filed by Unity Biotechnology, a company developing senolytic medicines, including small molecules that selectively eliminate senescent cells. J.M.v.D. is a co-founder of Unity Biotechnology. J.M.S. is a co-founder of Transposon Therapeutics, serves as chair of its Scientific Advisory Board and consults for Astellas Innovation Management, Atropos Therapeutics and Gilead Sciences. J.D.R. is a member of the Rutgers Cancer Institute of New Jersey and of the University of Pennsylvania Diabetes Research Center; a co-founder and stockholder in VL54, Sofro and Raze Therapeutics; and advisor and stockholder in Agios Pharmaceuticals, Kadmon Pharmaceuticals, Bantam Pharmaceuticals, Colorado Research Partners, Rafael Pharmaceuticals and L.E.A.F. Pharmaceuticals. J.B. has intellectual property related to the use of NAD precursors in liver regeneration. All other authors declare no conflict of interest. This research was conducted in compliance with Mayo Clinic Conflict of Interest policies.